John Chapman Articles
PCSK9 inhibition at the limits
With the PCSK9 inhibitors, are we now at the limit for LDL-C lowering? And if so, which patients are the priorities for this novel therapy in clinical practice? PCSK9 Forum Co-Editor Professor John Chapman discusses these important questions in this video. Pause 100/100 Production and…
read more »
The year in cardiology 2015: prevention
PCSK9 Forum Editors, Profs John Chapman, Ulf Landmesser and co-authors discuss the highlights of 2015 in The European Heart Journal.
read more »
From the Editors: PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
PCSK9 Forum Editors overview recent developments in PCSK9 science and therapeutics, culminating in regulatory approval of the first two PCSK9 monoclonal antibodies earlier this year. While access to this novel LDL lowering treatment will undoubtedly be influenced by local cost constraints, the editors highlight severe…
read more »
New era in cholesterol-lowering? PCSK9 inhibitors soon available?
European authority (CHMP) has recommended regulatory approval of the first PCSK9 inhibitor, opening the way to a new era of lowering LDL-cholesterol treatment for people with a high risk of heart attacks and strokes. The importance of this development and possible implications for patients with…
read more »
Is there a need for a unified definition for FH?
2014 FH Global Summit: 13-14 October, New York, USA: FH is clearly underdiagnosed and undertreated in the majority of countries.1 Given this status quo, would the development of a unified global definition of FH offer advantages for detection, management and health policy? In the FH…
read more »
